This review highlights the importance of oral anticoagulation management with vitamin K antagonists in atrial fibrillation and the need to increase time within therapeutic range.
Supports TTR optimization in VKA-treated AF; leaves open need for prospective validation of strategies.
Atrial fibrillation (AF) is a growing epidemic in the developed world that has attracted much attention due to the associated risk of stroke and thromboembolism. This article discusses the application of oral anticoagulation (OAC) therapy with vitamin K antagonists (VKA) in order to reduce these risks. The article provides an overview of OAC management and highlights the need for greater efforts to increase time within therapeutic range.
No takes yet. Share an insight, caveat, or question.
Taggar et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: